- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 10,845
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more
- Conditions
- Migraine
- Interventions
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
- Conditions
- Stroke, Patent Foramen Ovale
- Interventions
- AMPLATZER™ PFO Occluder
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Levonorgestrel, Placebo
- Other · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 66
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 46 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- PMD-026, fulvestrant
- Drug
- Lead sponsor
- Phoenix Molecular Designs
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Duarte, California • Irvine, California + 7 more
- Conditions
- Vasomotor Symptoms (VMS)
- Interventions
- MT-8554
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Core Binding Factor Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 65
- States / cities
- Lewes, Delaware • Newark, Delaware • Orlando, Florida + 44 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
- Drug · Behavioral
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 60
- States / cities
- Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
- Conditions
- Erosive Esophagitis
- Interventions
- BLI5100, PPI Control
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 122
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Peoria, Arizona + 99 more
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Not listed
- Lead sponsor
- TearLab Corporation
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 6
- States / cities
- San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more
- Conditions
- Cystic Fibrosis
- Interventions
- Recombinant Human DNase (Pulmozyme), Placebos
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Month to 30 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- ANG003
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
- Conditions
- Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
- Interventions
- Levosimendan, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
- Conditions
- Carotid Artery Disease
- Interventions
- MICHI NPS+f
- Device
- Lead sponsor
- Silk Road Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Orlando, Florida • Baltimore, Maryland + 15 more
- Conditions
- Asthma, Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 24 Years and older
- Enrollment
- 89,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Iowa City, Illinois • Research Triangle Park, North Carolina • Columbus, Ohio
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
- Interventions
- methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Thyrogen (thyrotropin alfa for injection)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- GSK4527363, Placebo matching GSK4527363, Belimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
- Conditions
- Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
- Conditions
- Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
- Conditions
- Hypertension
- Interventions
- Placebo, lorundrostat Dose 1, lorundrostat Dose 2
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 87
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more